Clinical Trial Detail

NCT ID NCT03586999
Title Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors University of Colorado, Denver
Indications

anaplastic large cell lymphoma

peripheral T-cell lymphoma

angioimmunoblastic T-cell lymphoma

liver lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Vincristine Sulfate

Age Groups: adult senior

Additional content available in CKB BOOST